1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 37, 15/Sep/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.37.2200697
2022-09-15
2025-02-23
/content/10.2807/1560-7917.ES.2022.27.37.2200697
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/37/eurosurv-27-37-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.37.2200697&mimeType=html&fmt=ahah

References

  1. Direção-Geral da Saúde. Norma 02/2021 - Campanha de Vacinação Contra a COVID-19 - Dose de Reforço. [Standard 02/2021 - Vaccination campaign against COVID-19 – Booster dose]. Lisbon: Direção-Geral da Saúde; 2021. Portuguese. Available from: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0022021-de-30012021-pdf.aspx
  2. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). COVID-19 : Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. EMA/204784/2022. Stockholm: ECDC, Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/documents/public-statement/covid-19-joint-statement-ecdc-ema-administration-fourth-dose-mrna-vaccines_.pdf
  3. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). COVID-19 : Updated joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. EMA/635144/2022. Stockholm: ECDC, Amsterdam: EMA;2022. Available from: https://www.ema.europa.eu/en/documents/public-statement/updated-joint-statement-ecdc-ema-additional-booster-doses-covid-19-vaccines_en.pdf
  4. Nunes B, Rodrigues AP, Kislaya I, Cruz C, Peralta-Santos A, Lima J, et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill. 2021;26(38):2100833.  https://doi.org/10.2807/1560-7917.ES.2021.26.38.2100833  PMID: 34558406 
  5. National Institute of Health (INSA) Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. 23 August 2022 report. Lisbon: INSA; 2022. Available from: https://insaflu.insa.pt/covid19/relatorios/PORTUGAL_INSA_SARS_CoV_2_GENETIC_DIVERSITY_situation_report_2022-09-06.pdf
  6. Ribeiro AI, Launay L, Guillaume E, Launoy G, Barros H. The Portuguese version of the european deprivation index: Development and association with all-cause mortality. PLoS One. 2018;13(12):e0208320.  https://doi.org/10.1371/journal.pone.0208320  PMID: 30517185 
  7. Link-Gelles R, Levy ME, Gaglani M, Irving SA, Stockwell M, Dascomb K, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931-9.  https://doi.org/10.15585/mmwr.mm7129e1  PMID: 35862287 
  8. Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ. 2022;378:e071502.  https://doi.org/10.1136/bmj-2022-071502  PMID: 35793826 
  9. Nordström P, Ballin M, Nordström A. Effectiveness of a second COVID-19 vaccine booster on all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden. SSRN Electron J. 2022:100466. Preprint.
  10. Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603-14.  https://doi.org/10.1056/NEJMoa2201688  PMID: 35417631 
  11. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30):2200551.  https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551  PMID: 35904059 
COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Irina+Kislaya&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kislaya Irina</a>, <a href="/search?value1=Ausenda+Machado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Machado Ausenda</a>, <a href="/search?value1=Sarah+Magalh%C3%A3es&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Magalhães Sarah</a>, <a href="/search?value1=Ana+Paula+Rodrigues&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rodrigues Ana Paula</a>, <a href="/search?value1=Rafael+Franco&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Franco Rafael</a>, <a href="/search?value1=Pedro+Pinto+Leite&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Leite Pedro Pinto</a>, <a href="/search?value1=Carlos+Matias+Dias&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dias Carlos Matias</a>, <a href="/search?value1=Baltazar+Nunes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nunes Baltazar</a></span>. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(37):pii=2200697. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.37.2200697" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.37.2200697</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 02 Sept 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 15 Sept 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.37.2200697
/content/10.2807/1560-7917.ES.2022.27.37.2200697
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error